Endoscopy Centre
Hong Kong, HONG KONG, China
NCT Number: NCT03028064
Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency. In an ageing population, antiplatelet drugs are increasingly being prescribed for treatment and prophylaxis against cardiovascular thrombo-embolic events. In many patients, platelet dysfunction mostly acquired is the principal cause of bleeding. To clinicians, the management of patients on antiplatelet drugs or anticoagulants is a challenge. One has to carefully balance the bleeding against thrombo-embolic risks. Therefore measuring platelet function should be integral in the management plan. A quantitative measurement allows titration of platelet function in accordance with bleeding or thromboembolic risk. Platelet function has not been studied in a large cohort of patients with acute upper gastrointestinal bleeding. As a first step, the study will determine if platelet dysfunction is associated with clinical outcome. In this prospective, observational single centre cohort study of consecutive patients with overt signs of acute upper gastrointestinal bleeding, their platelet function by point of care tests (light transmittance aggregometry, verify now p2y12,the platelet function analysis system (PFA-100) upon their admissions. Patients will be followed up for 30 days after trial enrollment. The primary endpoint is defined as significant bleeding that requires interventions (endoscopic, radiologic or surgery). Secondary end points include cardio- and cerebrovascular thrombo-embolic events and all cause deaths. A receiver operating characteristic (ROC) curve analysis is calculated for each point-of-care test to evaluate if individual test can distinguish between patients with and without primary end point. This study aims to evaluate the capability of platelet function tests to predict clinical outcome in patients with AUGIB. Logistic regression models will then be built in search for independent correlates to the primary and secondary endpoints and to adjust for confounding variables.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
Hong Kong, HONG KONG, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
in this cohort study, we will take blood to examine the platelet function
Time frame: within 30 days of trial inclusion
Data on whether patients experience further bleeding that requires interventions, the type of interventions and the time of further bleeding after trial inclusion, will be collected through electronic medical record
Time frame: within 30 days of trial inclusion
All cause deaths, cardiovascular or cerebral thrombotic events
Chinese University of Hong Kong
Other
Acronym: POCGIB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03955055
Digestive System Diseases, Gastro Intestinal Bleeding
Worcester, Massachusetts, United States
View Trial DetailsNCT06715293
Digestive System Diseases, Gastrointestinal Bleeding
Shatin, Hong Kong Island, Hong Kong
View Trial DetailsNCT00534677
Cirrhosis, Digestive System Diseases
Karachi, Sindh, Pakistan
View Trial DetailsNCT01131962
Digestive System Diseases, Esophageal Diseases
Alexandria, Egypt
View Trial Details